| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.087 | 0.1 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |